These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 33836264)

  • 21. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
    Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
    Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
    Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J
    Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Evolving Treatment Landscape in
    Tabernero J; Ros J; Élez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
    Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF
    García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S
    Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
    Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
    [No Abstract]   [Full Text] [Related]  

  • 29. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
    Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
    Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
    Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
    Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory
    Kawata A; Miyamoto Y; Fukubayashi K; Horio T; Miyamoto H; Ogawa K; Ouchi M; Tanaka Y; Baba H
    In Vivo; 2023; 37(4):1797-1801. PubMed ID: 37369457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
    Taieb J; Lonardi S; Desai J; Folprecht G; Gallois C; Marques EP; Khan S; Castagné C; Wasan H
    Clin Colorectal Cancer; 2023 Mar; 22(1):59-66. PubMed ID: 36653241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encorafenib plus cetuximab for the treatment of
    Ros J; Saoudi N; Baraibar I; Salva F; Tabernero J; Elez E
    Therap Adv Gastroenterol; 2022; 15():17562848221110644. PubMed ID: 35812780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of
    Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
    Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Lee HM; Morris V; Napolitano S; Kopetz S
    Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
    van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
    Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [BRAF V600E-mutant colorectal cancers: Where are we?].
    Lièvre A; de la Fouchardière C; Samalin E; Benoist S; Phelip JM; André T; Lledo G
    Bull Cancer; 2020 Sep; 107(9):881-895. PubMed ID: 32674932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.